Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Anteris Technologies Ltd (AVR.AX)
AUD12.57
-0.48 (-3.68%)
AU ASX Healthcare Medical - Devices
Address
Toowong Tower 4066
Toowong, QLD, AU
Toowong, QLD, AU
CEO
Wayne Geoffrey Paterson
Website
anteristech.com
IPO
2004-03-22
ISIN AU0000088841
Also trades on
Australian Securities Exchange · AVR.AX (AUD)
Other OTC · AMEUF (USD)
Description
Anteris Technologies Ltd is a firm specializing in the structural heart domain. It is responsible for the production and distribution of ADAPT, a product based on regenerative tissue technology. The company is also actively involved in advancing DurAVR™, an innovative 3D single-component aortic valve specifically designed for treating aortic stenosis. Additionally, Anteris allocates resources to the research and development of regenerative medicines. Founded in 1999, the enterprise was formerly known as Admedus Limited until it rebranded to Anteris Technologies Ltd in May 2020. Its primary operations are conducted from its base in Toowong, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD12.57
-0.48 (-3.68%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
20.9K
Beta
0.73
Float Shares
31.72M
Free Float %
86.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.42% | -5.62% | +59.35% | +39.43% | +103.82% | +60.18% | +88.77% | -48.03% | +51.86% | -65.44% | +652.76% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
12.57
Ratings Trend (MoM)
100% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-41.45
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Devices: +11.2%-56.2% Q4'25: -26.5% (vs Q4'23)
-
EPS growth Medical - Devices: +28.5%+57.1% ★ Q4'25: +11.7% (vs Q4'23)
-
FCF margin FCF growth · Medical - Devices: +30.9%-4,598.1% Q4'25: -1,461.3% (vs Q4'23)
-
EBIT margin Medical - Devices: +6.2%-4,921.7% Q4'25: -5,645.7% (vs Q4'23)
-
ROIC Medical - Devices: +3.3%— Q4'25: +2,772.8% (vs Q4'23)
-
Share dilution Medical - Devices: 0.0%+78.1% Q4'25: +123.7% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-0.02× Q4'25: -0.01× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2012 actual |
Dec 2013 actual |
Dec 2014 actual |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 3 Rev. Ana. 1 EPS Ana. |
Dec 2027 4 Rev. Ana. 1 EPS Ana. |
Dec 2028 4 Rev. Ana. 1 EPS Ana. |
Dec 2029 3 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
6.44M
est: 8.02M (-19.7%)
|
7.40M
est: 10.39M (-28.8%)
|
7.90M
est: 10.96M (-27.9%)
|
10.13M
est: 10.20M (-0.7%)
|
14.15M
est: 14.10M (+0.4%)
|
22.32M
est: 23.76M (-6.0%)
|
22.61M
est: 23.76M (-4.8%)
|
25.60M
est: 28.40M (-9.9%)
|
17.08M
est: 29.10M (-41.3%)
|
7.08M
est: 7.04M (+0.5%)
|
7.79M
est: 6.80M (+14.5%)
|
4.59M
est: 7.48M (-38.7%)
|
4.11M
est: 3.89M (+5.7%)
|
4.37M
est: 4.57M (-4.3%)
|
1.91M
est: 2.58M (-25.9%)
|
10.98M
8.68M – 14.64M
+325.6% YoY
|
19.77M
9.82M – 31.86M
+80.0% YoY
|
23.41M
14.45M – 35.05M
+18.4% YoY
|
230.34M
142.20M – 344.88M
+884.0% YoY
|
442.32M
273.07M – 662.27M
+92.0% YoY
|
| EBITDA |
-3.64M
est: -8.02M (+54.6%)
|
-4.15M
est: -31.13M (+86.7%)
|
-13.18M
est: -32.83M (+59.9%)
|
-22.88M
est: -10.20M (-124.3%)
|
-27.81M
est: -31.38M (+11.4%)
|
-14.07M
est: -18.43M (+23.7%)
|
-15.89M
est: -18.43M (+13.8%)
|
-22.23M
est: -27.62M (+19.5%)
|
-4.06M
est: -29.10M (+86.1%)
|
-15.64M
est: -7.04M (-122.1%)
|
-21.42M
est: -6.80M (-214.9%)
|
-43.03M
est: -7.48M (-475.1%)
|
-66.90M
est: -3.89M (-1,620.8%)
|
-112.11M
est: -4.57M (-2,355.5%)
|
-92.49M
est: -2.58M (-3,484.1%)
|
-10.98M
-14.64M – -8.68M
-325.6% YoY
|
-19.77M
-31.86M – -9.82M
-80.0% YoY
|
-23.41M
-35.05M – -14.45M
-18.4% YoY
|
-230.34M
-344.88M – -142.20M
-884.0% YoY
|
-442.32M
-662.27M – -273.07M
-92.0% YoY
|
| EBIT |
-3.92M
est: -8.02M (+51.1%)
|
-4.36M
est: -32.57M (+86.6%)
|
-14.60M
est: -34.36M (+57.5%)
|
-23.80M
est: -10.20M (-133.3%)
|
-25.06M
est: -32.84M (+23.7%)
|
-12.62M
est: -18.97M (+33.5%)
|
-17.54M
est: -18.97M (+7.5%)
|
-22.06M
est: -25.13M (+12.2%)
|
-5.89M
est: -29.10M (+79.8%)
|
-16.85M
est: -7.04M (-139.3%)
|
-22.78M
est: -6.80M (-234.9%)
|
-44.78M
est: -7.48M (-498.4%)
|
-69.69M
est: -3.89M (-1,692.6%)
|
-114.40M
est: -4.57M (-2,405.5%)
|
-94.15M
est: -2.58M (-3,548.4%)
|
-10.98M
-14.64M – -8.68M
-325.6% YoY
|
-19.77M
-31.86M – -9.82M
-80.0% YoY
|
-23.41M
-35.05M – -14.45M
-18.4% YoY
|
-230.34M
-344.88M – -142.20M
-884.0% YoY
|
-442.32M
-662.27M – -273.07M
-92.0% YoY
|
| Net Income |
-10.00M
est: -94.50M (+89.4%)
|
-1.89M
est: -31.13M (+93.9%)
|
-6.62M
est: -32.83M (+79.8%)
|
-25.25M
est: -240.36M (+89.5%)
|
-24.01M
est: -31.38M (+23.5%)
|
-12.31M
est: -18.43M (+33.2%)
|
-17.26M
est: -18.43M (+6.3%)
|
-24.22M
est: -41.92M (+42.2%)
|
-5.82M
est: -40.51M (+85.6%)
|
-15.27M
est: -62.78M (+75.7%)
|
-22.91M
est: 117.26M (-119.5%)
|
-44.34M
est: -44.96M (+1.4%)
|
-67.33M
est: -196.66M (+65.8%)
|
-123.26M
est: -184.58M (+33.2%)
|
-94.14M
est: -95.30M (+1.2%)
|
-62.41M
-95.62M – -29.19M
+34.5% YoY
|
-64.28M
-98.49M – -30.06M
-3.0% YoY
|
-44.37M
-67.98M – -20.75M
+31.0% YoY
|
-34.19M
-56.29M – -17.18M
+22.9% YoY
|
-25.63M
-42.20M – -12.88M
+25.0% YoY
|
| SGA |
3.98M
est: 37.04M (-89.3%)
|
4.32M
est: 48.01M (-91.0%)
|
9.15M
est: 50.63M (-81.9%)
|
19.47M
est: 47.11M (-58.7%)
|
24.00M
est: 65.13M (-63.1%)
|
5.52M
est: 109.75M (-95.0%)
|
26.48M
est: 109.75M (-75.9%)
|
29.94M
est: 131.18M (-77.2%)
|
22.42M
est: 134.41M (-83.3%)
|
12.36M
est: 32.53M (-62.0%)
|
10.51M
est: 31.42M (-66.5%)
|
16.08M
est: 34.56M (-53.5%)
|
24.95M
est: 27.22M (-8.3%)
|
45.54M
est: 31.96M (+42.5%)
|
26.12M
est: 18.07M (+44.6%)
|
76.89M
60.79M – 102.51M
+325.6% YoY
|
138.41M
68.77M – 223.02M
+80.0% YoY
|
163.87M
101.17M – 245.36M
+18.4% YoY
|
1.61B
995.48M – 2.41B
+884.0% YoY
|
3.10B
1.91B – 4.64B
+92.0% YoY
|
| EPS |
-0.72
est: -4.67 (+84.6%)
|
-0.14
est: -0.99 (+85.9%)
|
-5.44
est: -9.94 (+45.3%)
|
-1.83
est: -11.87 (+84.6%)
|
-1.74
est: -10.49 (+83.4%)
|
-0.89
est: -5.25 (+83.0%)
|
-6.78
est: -5.25 (-29.1%)
|
-1.75
est: -2.00 (+12.5%)
|
-0.42
est: -2.00 (+79.0%)
|
-1.11
est: -3.10 (+64.2%)
|
-1.66
est: 5.79 (-128.7%)
|
-3.21
est: -2.22 (-44.6%)
|
-4.31
est: -5.08 (+15.1%)
|
-6.09
est: -4.76 (-27.8%)
|
-2.61
est: -3.29 (+20.6%)
|
-1.61
-2.65 – -0.81
+51.0% YoY
|
-1.66
-2.73 – -0.83
-3.0% YoY
|
-1.14
-1.89 – -0.58
+31.0% YoY
|
-0.95
-1.56 – -0.48
+17.2% YoY
|
-0.71
-1.17 – -0.36
+25.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-104.36M
OE per share TTM
-4.41
Owner's Yield
-23.59%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
78.8%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-6.9K
Shares Outstanding
36.79M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Wayne Geoffrey Paterson | Vice Chairman & Chief Executive Officer | 2M | male |
| David Denis | President & Director | 1M | male |
| Matthew McDonnell | Chief Financial Officer | 637.8K | male |
| Chris Meduri | Chief Medical Officer & Member of Medical Advisory Board | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVR.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
